1. Home
  2. CNOB vs MPLT Comparison

CNOB vs MPLT Comparison

Compare CNOB & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ConnectOne Bancorp Inc.

CNOB

ConnectOne Bancorp Inc.

SELL

Current Price

$30.35

Market Cap

1.6B

Sector

Finance

ML Signal

SELL

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

BUY

Current Price

$7.71

Market Cap

1.7B

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
CNOB
MPLT
Founded
1982
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
1995
2025

Fundamental Metrics

Financial Performance
Metric
CNOB
MPLT
Price
$30.35
$7.71
Analyst Decision
Buy
Strong Buy
Analyst Count
5
15
Target Price
★ $36.75
$26.54
AVG Volume (30 Days)
339.2K
★ 422.3K
Earning Date
10-22-2026
12-03-2026
Dividend Yield
★ 2.56%
N/A
EPS Growth
N/A
★ 82.39
EPS
★ 1.51
N/A
Revenue
N/A
N/A
Revenue This Year
$28.95
N/A
Revenue Next Year
$8.74
N/A
P/E Ratio
$20.16
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.20
$7.46
52 Week High
$34.14
$40.43

Technical Indicators

Market Signals
Indicator
CNOB
MPLT
Relative Strength Index (RSI) 45.31 23.77
Support Level $29.33 N/A
Resistance Level $30.57 $20.46
Average True Range (ATR) 0.58 0.60
MACD 0.05 -0.03
Stochastic Oscillator 63.56 8.81

Price Performance

Historical Comparison
CNOB
MPLT

About CNOB ConnectOne Bancorp Inc.

ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets, and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental, and consumer wages.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: